Training & Education

Mammography Topics

AI and DBT in Screening: Approaches to Improve and Accelerate Mammography Reading

Digital breast tomosynthesis (DBT) is being intensively discussed for use European screening programs, while it’s already being widely adopted in the United States. Within DBT, reading time is of the essence and any effort to reduce it will be particularly important. Artificial Intelligence (AI) assisted navigating and reading could also have a substantial impact on reading time (Sechopolous, ECR March 2020).

Experts are describing a number of strategies for reducing the number of cases and images that need to be interpreted and are proposing various methods for decreasing the time required to interpret a case. Artificial intelligence is one of the latest developments that can reduce reading time and even improve the diagnostic outcome.

Artificial intelligence in breast imaging: chances, challenges, and concerns

The expert panel with Prof. Dr. Sylvia Heywang-Köbrunner, Dr. Solveig Hofvind and Dr. Ritse Mann shed light on the role of Artificial Intelligence in the clinical routine of breast cancer screening and diagnostics. They discuss the chances, challenges, and concerns that put the use of AI in mammography and tomosynthesis to the test. (ECR, March, 2023)

Artificial intelligence in breast imaging: chances, challenges, and concerns - Interview

Dr. Ritse Mann summarizes the chances, challenges and concerns related to Artificial Intelligence in breast imaging, screening and diagnostics. (ECR, March, 2023)

The contribution of wide-angle DBT and AI-based CAD in the detection of interval cancers

Prof. Dr. Sophia Zackrisson (Lund University Malmö, Sweden) talks about the recent insight from the Malmö Breast Tomosynthesis Screening Trial and explain the contribution of wide-angle Breast Tomosynthesis in the detection of interval cancers - which she published in Radiology.

Dr. Alejandro Rodriguez-Ruiz (Nijmegen, The Netherlands) focuses on the role of artificial intelligence for the reduction of interval cancer rates. (April 2021)